RedHill Biopharma Ltd. (RDHL) Key Metrics
RDHL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.3M
- Enterprise value
- $413,101
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 10.2
- Price / book
- 0.8
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 4.90
RDHL key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRDHL valuation Price multiples at each fiscal year-end price.
RDHL returns How much profit the business earns on the capital it uses.
RDHL per-share figures Results divided by the shares outstanding at year-end.
RDHL financial health Debt, liquidity and how easily interest is covered.
RDHL efficiency & capital use Working capital cycle and where the cash goes.
RDHL valuation history
RDHL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RDHL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RDHL price vs earnings per share
RDHL key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.3M | $15.3M | — | — | — | — | — | — | — | — |
| Enterprise value | $352,950 | $11.0M | — | — | — | — | — | — | — | — |
| Price / sales | 11.4 | 1.9 | — | — | — | — | — | — | — | — |
| Price / book | 0.8 | — | — | — | — | — | — | — | — | — |
| EV / sales | 1.2 | 1.4 | — | — | — | — | — | — | — | — |
| Earnings yield | −13.2% | −54.0% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −296.7% | −61.3% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.03 | $6.21 | $36.50 | $140.30 | $2,580.00 | $8,080.00 | $6,070.00 | $5,550.00 | $5,140.00 | $10,460.00 |
| Per share | ||||||||||
| Revenue per share | $0.09 | $3.26 | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.14 | −$3.35 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$3.05 | −$3.80 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$3.06 | −$3.81 | — | — | — | — | — | — | — | — |
| Cash per share | $1.26 | $1.87 | — | — | — | — | — | — | — | — |
| Book value per share | $1.35 | −$1.90 | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$0.32 | −$4.15 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $0.34 | $0.14 | — | — | — | — | — | — | — | — |
| Shares outstanding | 3.2M | 2.5M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +28.2% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −859.7% | −206.2% | −76.1% | −80.7% | −84.5% | −47.8% |
| Return on invested capital (ROIC) | — | — | — | −59.9% | −98.9% | −115.8% | −489.4% | — | — | −821.0% |
| Return on assets (ROA) | −2.0% | −40.2% | 26.3% | −42.2% | −54.1% | −59.9% | −62.0% | −64.8% | −69.2% | −41.6% |
| Return on tangible assets | −2.1% | −66.2% | 136.9% | −76.9% | −89.2% | −82.5% | −74.0% | −68.0% | −87.5% | −43.1% |
| Free cash flow margin | — | −116.6% | −548.7% | −47.5% | −76.0% | −159.0% | −651.0% | −412.9% | — | — |
| Income quality (OCF / net income) | — | — | −1.50 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.1M | $356,000 | $1.2M | $122.7M | $87.8M | $86.9M | $3.8M | — | $448,000 | $6.2M |
| Cash & short-term investments | $4.0M | $4.6M | $6.4M | $20.0M | $38.0M | $29.8M | $47.9M | $53.2M | $46.2M | $66.2M |
| Net debt | −$2.9M | −$4.3M | −$5.2M | $102.7M | $49.8M | $57.1M | −$44.1M | −$53.2M | −$45.8M | −$60.0M |
| Debt / equity | 0.25 | — | 0.57 | — | 9.89 | 6.27 | 0.06 | — | 0.01 | 0.10 |
| Debt / assets | 0.04 | 0.02 | 0.05 | 0.77 | 0.48 | 0.48 | 0.05 | — | 0.01 | 0.08 |
| Net debt / EBITDA | — | — | −0.20 | — | — | — | — | — | — | — |
| Current ratio | 0.34 | 0.54 | 0.84 | 0.44 | 1.09 | 0.96 | 5.01 | 5.47 | 4.37 | 12.66 |
| Quick ratio | 0.34 | 0.37 | 0.61 | 0.38 | 0.91 | 0.87 | 4.84 | 5.40 | 4.31 | 12.45 |
| Interest coverage | -416.3 | -265.7 | 34.4 | -1.0 | -4.9 | -5.1 | -98.3 | -235.5 | -675.0 | — |
| Working capital | −$12.7M | −$10.3M | −$3.1M | −$111.6M | $7.7M | −$2.7M | $42.6M | $46.4M | $39.8M | $62.5M |
| Invested capital | $1.4M | −$8.9M | −$3.1M | $54.3M | $58.7M | $71.0M | $15.9M | −$2.0M | −$692,000 | $2.7M |
| Tangible asset value | −$1.0M | −$10.2M | −$3.5M | −$114.0M | −$62.8M | −$74.0M | $43.1M | $45.9M | $39.8M | $56.6M |
| Net current asset value | −$14.5M | −$10.8M | −$4.8M | −$121.4M | −$83.2M | −$95.9M | $39.1M | $45.6M | $39.4M | $56.3M |
| Graham net-net per share | −$4.83 | −$5.52 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Capex / revenue | 1.7% | 0.1% | 0.2% | 0.3% | 0.1% | 83.6% | 3.2% | 0.7% | 29.5% | 118.8% |
| Capex / depreciation | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 6.15 | 0.17 | 0.64 | 14.58 | 2.73 |
| Stock-based compensation / revenue | 159.8% | 8.3% | 25.2% | 9.2% | 11.9% | 6.5% | 48.1% | 32.0% | 55.8% | 1,662.4% |
| R&D / revenue | 707.3% | 19.7% | 54.0% | 11.8% | 34.4% | 25.6% | 276.9% | 297.4% | 822.8% | 24,991.1% |
| SG&A / revenue | 2,158.0% | 192.9% | 442.3% | 103.6% | 102.6% | 116.0% | 473.9% | 239.1% | 500.1% | 5,349.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 3,857.4 | 155.5 | 1,150.3 | 207.9 | 131.5 | 87.7 | 87.9 | 79.8 | 125.4 | 1,286.5 |
| Days of inventory on hand | — | 459.7 | 812.4 | 141.3 | 78.8 | 41.6 | 214.2 | 91.5 | 151.7 | -199.3 |
| Days payables outstanding | — | 636.9 | 396.1 | 87.0 | 85.8 | 77.8 | 606.6 | 522.9 | 417.6 | 1.1 |
| Cash conversion cycle (days) | — | -21.7 | 1,566.6 | 262.2 | 124.6 | 51.4 | -304.5 | -351.6 | -140.5 | 1,086.2 |
| Receivables turnover | 0.09 | 2.35 | 0.32 | 1.76 | 2.77 | 4.16 | 4.15 | 4.57 | 2.91 | 0.28 |
| Payables turnover | 0.00 | 0.57 | 0.92 | 4.19 | 4.26 | 4.69 | 0.60 | 0.70 | 0.87 | 341.26 |
| Inventory turnover | — | 0.79 | 0.45 | 2.58 | 4.63 | 8.78 | 1.70 | 3.99 | 2.41 | — |
| Asset turnover | 0.01 | 0.39 | 0.07 | 0.36 | 0.47 | 0.51 | 0.09 | 0.14 | 0.06 | 0.00 |
| Average receivables | $3.0M | $3.4M | $20.6M | $35.2M | $30.9M | $15.5M | $1.5M | $1.8M | $1.4M | $356,000 |
| Average payables | $7.1M | $5.6M | $3.8M | $7.9M | $11.6M | $7.9M | $3.8M | $4.1M | $2.4M | $89,500 |
| Average inventory | $1.8M | $4.0M | $7.7M | $12.9M | $10.7M | $4.2M | $1.3M | $711,000 | $883,500 | −$16.7M |
| Intangibles / total assets | 20.9% | 30.7% | 24.2% | 41.3% | 39.5% | 48.8% | 22.8% | 8.5% | 9.2% | 8.2% |
Computed from RDHL's annual financial statements (latest annual report filed April 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RDHL valuation and financial ratios
It ended the year with $1.1 million of debt and $4.0 million in cash and short-term investments, a net cash position of $2.9 million.
See the RDHL income statement, the RDHL chart for price history, or the RDHL stock overview for the latest quote and news.
RDHL key metrics FAQ
How much debt does RedHill Biopharma have?
RedHill Biopharma had total debt of $1.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.25 and more cash than debt.
What is RedHill Biopharma's free cash flow yield?
RedHill Biopharma generated -$9.7 million of free cash flow in fiscal 2025, a free cash flow yield of −296.7% on its market value at year-end ($3.3 million).
What is RedHill Biopharma's current ratio?
RedHill Biopharma's current ratio was 0.34 at the end of fiscal 2025: current assets were 0.34 times current liabilities.